Publication of Phase 3 STRATA2016 Study in Burns Peer Review Journal

Dr. Steve Romano, MD, Executive Vice President and Chief Scientific Officer at Mallinckrodt Pharmaceuticals discusses the results of their pivotal Phase 3 STRATA2016 clinical trial of StrataGraft ®, an allogeneic cellularized scaffold product for the treatment of adult patients with deep partial-thickness burns. The data was published in “Burns” peer review journal (August 2021). It received FDA approval in June 2021 and can provide burn surgeons with an alternative biologic treatment option for patients with deep partial-thickness burns.

Dr. Steven Romano is executive vice president and chief scientific officer at Mallinckrodt Pharmaceuticals. He has executive responsibility for research and development (R&D), medical affairs and regulatory affairs functions, and is a member of Mallinckrodt’s executive committee. A board-certified psychiatrist, Dr. Romano has more than 20 years of experience in the pharmaceutical industry. Prior to joining Mallinckrodt, he spent 16 years at Pfizer, Inc. where he held a series of senior medical and R&D roles of increasing responsibility, culminating in his most recent position as SVP, Head, Global Medicines Development, Global Innovative Pharmaceuticals Business. Prior to joining Pfizer, he spent four years at Eli Lilly.

After receiving an A.B. in biology from Washington University and a medical degree from the University of Missouri-Columbia, Dr. Romano completed his residency and fellowship at New York Hospital-Cornell Medical Center, continuing on the faculty of the medical school for six additional years.